Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Avapritinib
|
| gptkbp:activities |
inhibitor of mutant KIT and PDGFRA
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 1
combination therapy Phase 2 Phase 3 monotherapy |
| gptkbp:contraindication |
hypersensitivity to avapritinib
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
feces
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:has_ability |
100 mg
300 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Ayvakit
|
| gptkbp:indication |
advanced GIST
|
| gptkbp:ingredients |
avapritinib
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 XX
|
| gptkbp:is_used_for |
treatment of gastrointestinal stromal tumors (GIS Ts)
|
| gptkbp:label |
prescribing information
|
| gptkbp:lifespan |
approximately 10-12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Blueprint_Medicines_Corporation
|
| gptkbp:marketed_as |
gptkb:2020
|
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:pharmacokinetics |
oral bioavailability
|
| gptkbp:population |
adults
|
| gptkbp:provides_information_on |
ESMO guidelines
NCCN guidelines |
| gptkbp:research_focus |
kinase inhibitors
targeted therapy precision medicine GIST treatment |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea weight loss abdominal pain vomiting decreased appetite diarrhea thromboembolic events dry skin insomnia skin rash muscle spasms elevated liver enzymes hypophosphatemia peripheral edema |
| gptkbp:social_structure |
C22 H24 N4 O2 S
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:type_of |
1416320-36-0
|